Sign in Subscribe

Industry News

M&A, deals, financial results, company news

Feedback from the J.P. Morgan Conference

Feedback from the J.P. Morgan Conference

The 44th Annual J.P. Morgan Healthcare Conference took place from January 12-15, 2026, in San Francisco. Although we have not been present physically in San Francisco, we have been able to connect into several panel discussions and get access to some presentations. Of course, what is missing is the

2025: A turbulent year for the biotechnology industry

2025: A turbulent year for the biotechnology industry

CEOS of biotech companies and financial investors assess the year 2025 with a different viewpoint.

Roche and Alzheimer’s disease

Roche and Alzheimer’s disease

SPECIAL REPORT 25.09 Roche and Alzheimer’s disease On July 28, at the Alzheimer’s Association International Conference (AAIC) held in Toronto (Canada), Roche presented new data from its development portfolio including additional diagnostics outcomes. In several oral presentations Roche disclosed its latest results from the ongoing trontinemab’s

Sanofi au plus bas depuis trois ans.

Sanofi au plus bas depuis trois ans.

SPECIAL REPORT 25.08 Sanofi au plus bas depuis trois ans. Chers anciens collègues, Ancien salarié et dirigeant de Sanofi je reste, comme de nombreux d’entre vous, très attentif à son évolution. Le 31 juillet est à nouveau une journée sombre pour le Groupe puisque le cours de son

Abivax: Ahead of a bright future?

Abivax: Ahead of a bright future?

SPECIAL REPORT 25.07 Abivax: Ahead of a bright future? On Tuesday, July 22, just after the closure of Wall Street, Abivax announced positive phase 3 results for the treatment of ulcerative colitis (UC). The Paris and Boston-based biotechnology company conducted two clinical studies (ABTECT-1 and ABTECT-2 in 8 week

Targeted protein degradation

Targeted protein degradation

SPECIAL REPORT 25.5 Scientific publication This article was published in a different format in the April issue of MedNous Learn more The development of new drugs is dependent on many factors, and one of the most important is being able to identify and reach a target. For years, a

The European Commission approves Leqembi®

The European Commission approves Leqembi®

Scientific publication This article was published in a different format in the April issue of MedNous The Alzheimer’s disease drug, Leqembi® (lecanemab), has been approved by the European Commission following extra reviews of the product’s safety. The decision was announced on 16 April by the product’s co-developer